What's Happening?
Corcept Therapeutics will present new data from its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 ESMO Annual Meeting. The trial focuses on patients previously treated with a PARP inhibitor, a group with poor prognosis. Relacorilant is a selective glucocorticoid receptor antagonist that modulates cortisol activity, and has been designated an orphan drug by the FDA and European Commission for ovarian cancer treatment. The presentation will occur on October 19, 2025, during a mini oral session on gynecological cancers.
Why It's Important?
The presentation of relacorilant's trial data is crucial as it addresses the treatment of platinum-resistant ovarian cancer, a condition with limited options and poor survival rates. Corcept's research could lead to new therapeutic strategies, improving outcomes for patients with this challenging cancer type. The designation of relacorilant as an orphan drug highlights its potential significance in addressing unmet medical needs. Successful trial results could pave the way for regulatory approval and expanded use in oncology, impacting patient care and treatment protocols.
What's Next?
Corcept Therapeutics is expected to continue its clinical trials and research on relacorilant, with upcoming Prescription Drug User Fee Act (PDUFA) dates for its approval as a treatment for hypercortisolism and ovarian cancer. The company will likely focus on further development and potential commercialization of relacorilant, aiming to enhance its therapeutic portfolio and address serious disorders through cortisol modulation.
